ATX-559, a first-in-class oral DHX9 inhibitor, shown to induce potent and selective tumor growth inhibition in preclinical models of cancers with high genomic instability and replication stress Oral ...
KYTHERA Biopharmaceuticals, Inc.today announced it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ATX-101 (deoxycholic acid) as an injectable treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results